NCT06469645View on ClinicalTrials.gov

The Role of SGLT2i in Management of Moderate AS

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Moderate Aortic Valve Stenosis
Interventions
DRUG

Empagliflozin 10 MG

Participants allocated in the Intervention Group will be taking empagliflozin 10mg once a day on top of their regular medications.

Trial Locations (1)

Unknown

RECRUITING

Norfolk and Norwich University Hospital, Norwich

All Listed Sponsors
collaborator

Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

OTHER

lead

University of East Anglia

OTHER